Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Payables (2016 - 2025)

China Pharma Holdings filings provide 16 years of Payables readings, the most recent being $4.0 million for Q4 2025.

  • On a quarterly basis, Payables rose 20.14% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a 20.14% increase, with the full-year FY2025 number at $4.0 million, up 20.14% from a year prior.
  • Payables hit $4.0 million in Q4 2025 for China Pharma Holdings, up from $2.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $6.4 million in Q3 2022 to a low of $349805.0 in Q2 2022.
  • Median Payables over the past 5 years was $2.6 million (2023), compared with a mean of $2.7 million.
  • The widest YoY moves for Payables: up 970.19% in 2022, down 66.63% in 2022.
  • China Pharma Holdings' Payables stood at $1.5 million in 2021, then surged by 196.57% to $4.5 million in 2022, then plummeted by 52.98% to $2.1 million in 2023, then skyrocketed by 58.46% to $3.3 million in 2024, then rose by 20.14% to $4.0 million in 2025.
  • The last three reported values for Payables were $4.0 million (Q4 2025), $2.0 million (Q3 2025), and $3.8 million (Q2 2025) per Business Quant data.